Latest Ratios: P/E Ratio -15.1x · EV/EBITDA N/A · ROE -135.6%. (2019–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Market Cap | $1.5B | $285M | $781M | $5.1B | $6.6B | $10.1B | — | — |
| Enterprise Value | $1.4B | $148M | $631M | $5.1B | $6.2B | $9.1B | — | — |
| P/E Ratio → | -15.10 | — | — | — | — | — | — | — |
| P/S Ratio | 0.25 | 0.05 | 0.13 | 1.19 | 2.76 | 6.62 | — | — |
| P/B Ratio | 11.83 | 2.25 | 1.66 | 7.76 | 6.33 | 9.22 | — | — |
| P/FCF | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 0.02 | 0.10 | 1.17 | 2.59 | 5.96 | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | -3.2% | -3.2% | 0.1% | 1.6% | 4.7% | 4.3% | 7.7% | 3.6% |
| Operating Margin | -7.1% | -7.1% | -4.8% | -5.4% | -4.4% | -24.5% | -4.7% | -13.4% |
| Net Profit Margin | -6.8% | -6.8% | -4.3% | -6.1% | -4.5% | -26.7% | -4.9% | -35.6% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| ROE | -135.6% | -135.6% | -46.0% | -30.9% | -10.0% | -100.8% | — | — |
| ROA | -27.0% | -27.0% | -15.0% | -15.3% | -6.5% | -40.0% | -14.1% | -70.2% |
| ROIC | -203.2% | -203.2% | -47.6% | -28.4% | -21.8% | -289.6% | — | — |
| ROCE | -108.4% | -108.4% | -43.4% | -24.1% | -8.8% | -52.8% | -29.6% | -52.5% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.29 | 0.29 | 0.09 | 0.08 | 0.05 | 0.05 | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -1.08 | -0.32 | -0.09 | -0.40 | -0.91 | — | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — |
| Interest Coverage | -59.85 | -59.85 | -39.28 | -28.21 | -19.22 | -61.31 | -6.66 | -11.65 |
Net cash position: cash ($174M) exceeds total debt ($37M)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.02 | 1.02 | 1.27 | 1.51 | 2.71 | 3.83 | 1.10 | 1.23 |
| Quick Ratio | 1.02 | 1.02 | 1.27 | 1.51 | 2.71 | 3.83 | 1.10 | 1.23 |
| Cash Ratio | 0.26 | 0.26 | 0.35 | 0.51 | 1.64 | 2.96 | 0.40 | 0.62 |
| Asset Turnover | — | 4.67 | 3.50 | 2.48 | 1.41 | 0.96 | 2.73 | 1.97 |
| Inventory Turnover | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | 41.45 | 61.25 | 79.70 | 75.25 | 70.39 | 43.31 | 42.85 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.2% | 1.1% | 0.0% | 3.9% | 0.0% | 0.0% | — | — |
| Total Shareholder Yield | 0.2% | 1.1% | 0.0% | 3.9% | 0.0% | 0.0% | — | — |
| Shares Outstanding | — | $17M | $16M | $16M | $16M | $15M | $15M | $15M |
Includes 30+ ratios · 7 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying AGL stock.
Agilon Health, Inc.'s current P/E ratio is -15.1x. This places it at the 50th percentile of its historical range.
Agilon Health, Inc.'s return on equity (ROE) is -135.6%. The historical average is -64.6%.
Based on historical data, Agilon Health, Inc. is trading at a P/E of -15.1x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Agilon Health, Inc. has -3.2% gross margin and -7.1% operating margin.
Key Metrics
Top Statement Risk
Persistent negative unit economics
Metrics are mathematically derived from official filings.
Valuation Rests on Book Value Not Earnings
As reported in AGL's filings, the P/E of -4.63 is not meaningful given losses, leaving P/B of 14.82 and P/S of 0.32 as the only usable multiples, and the wide gap between them signals that the market is pricing future recovery rather than current earnings power.
A negative P/E means earnings-based comparison is unavailable, so the analysis relies on sales and book value multiples. The P/S of 0.32 appears low against peers with positive margins, which may reflect the market discounting revenue that is not converting into profit. The P/B of 14.82 is elevated relative to a shrinking equity base, suggesting investors may be assigning value to the 20-year physician contract moat rather than to tangible book value, an assumption that warrants further investigation.
Margins Recovering But Remain Below Breakeven
Based on AGL's reported figures, gross margin improved to 6.4% and operating margin to 1.6% in Q3 2026 from deeply negative levels in late 2025, yet net margin of 2.3% rests on a single quarter that is not yet confirmed as durable.
Operating margin remains thin and is below the 4.1% to 6.2% gross margin range seen in earlier quarters, indicating SG&A still absorbs most gross profit. Compared with peers such as Elevance at 2.8% net margin and Molina at 1.0%, AGL's latest quarter is competitive, but its ten-quarter history of sharp reversals suggests the recovery may reflect timing of medical cost recognition rather than structural improvement. Investors should monitor whether gross margin holds above zero across several consecutive quarters.
Returns Swing Sharply With Thin Equity Base
According to reported ratios, ROIC moved from -144.8% in Q4 2025 to 12.3% in Q3 2026, but this swing is amplified by shrinking invested capital and a negative retained earnings balance rather than reflecting a steady compounding trajectory.
Return metrics appear distorted by the equity base, which fell sharply before partially rebounding, so percentage returns overstate the quality of the latest print. ROE of 13.7% against peers like Elevance at 11.6% looks favorable, but investors should weigh this against the Q3 2026 equity increase that may reflect non-operating items. Sustained ROIC above the cost of capital would require several more quarters of positive operating income before the trend can be treated as compounding.
Low Debt Load Masks Operating Fragility
Based on AGL's reported figures, debt-to-equity of 0.12 and debt-to-EBITDA of 1.08 appear conservative, yet interest coverage swung from -108.30x to 23.31x across recent quarters, indicating coverage is driven by volatile earnings rather than a stable cushion.
The low absolute debt level, roughly $33M to $46M, limits refinancing pressure and suggests minimal exposure to rising rates. However, interest coverage metrics are unreliable as a comfort indicator because the denominator, operating income, has been negative for much of the period. Investors should treat the current leverage profile as adequate on paper while monitoring whether coverage stabilizes above a meaningful threshold.
Misapplied Ratio Obscures Medical Cost Reality
The P/B ratio is most commonly misapplied to AGL, as its 14.82 level and shrinking book value obscure whether the 20-year contract base provides durable economic value versus intangible goodwill that may not be recoverable.
Applying P/B to a physician enablement platform treats goodwill and contract intangibles as equivalent to tangible assets, which may overstate the cushion available to shareholders. A more informative alternative is medical margin per member, which isolates the spread between capitation revenue and medical claims before overhead. Investors should weigh this unit economic measure more heavily than book value multiples when assessing whether the business model is improving.